10.07.2024 07:30:13
|
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: EVOTEC SE
/ Key word(s): Miscellaneous
Hamburg, Germany, 10 July 2024: The research will be carried out at Evotec’s sites in France, including Campus Curie in Toulouse, a state-of-the-art research site with capabilities spanning high throughput screening, in vitro and in vivo biology, proteomics and metabolomics. Evotec will receive research support funding from Pfizer and be eligible for potential milestones and royalties related to success of the programs. Dr Matthias Evers, Chief Business Officer at Evotec, commented: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. France has established a thriving biopharmaceutical ecosystem to which Evotec also contributes with its strong presence with more than 1,000 employees at our French sites, building a strong pipeline of medicines that matter. Focussing on diseases with severe unmet medical need and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D activities.” Dr Luca Mollo, Vice President and Medical Lead France at Pfizer, commented: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need”.
About Evotec SE Forward-looking-statements
For further information, please contact: Media Gabriele Hansen Hinnerk Rohwedder Investor Relations Volker Braun
10.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Evotec SE |
Manfred Eigen Campus / Essener Bogen 7 | |
22419 Hamburg | |
Germany | |
Phone: | +49 (0)40 560 81-0 |
Fax: | +49 (0)40 560 81-222 |
E-mail: | info@evotec.com |
Internet: | www.evotec.com |
ISIN: | DE0005664809 |
WKN: | 566480 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: | 1942469 |
End of News | EQS News Service |
|
1942469 10.07.2024 CET/CEST
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu EVOTEC SEmehr Nachrichten
11.12.24 |
Angespannte Stimmung in Frankfurt: TecDAX beendet den Handel in der Verlustzone (finanzen.at) | |
11.12.24 |
Mittwochshandel in Frankfurt: SDAX am Mittwochmittag im Aufwind (finanzen.at) | |
11.12.24 |
Anleger in Frankfurt halten sich zurück: TecDAX legt am Mittag den Rückwärtsgang ein (finanzen.at) | |
11.12.24 |
Schwacher Wochentag in Frankfurt: TecDAX verbucht zum Start des Mittwochshandels Abschläge (finanzen.at) | |
11.12.24 |
Handel in Frankfurt: SDAX zum Start antriebslos (finanzen.at) | |
11.12.24 |
EQS-News: Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk (EQS Group) | |
11.12.24 |
EQS-News: Evotec SE kündigt erste Projekte für den LAB eN² Accelerator mit Novo Nordisk an (EQS Group) | |
10.12.24 |
Börse Frankfurt: Das macht der SDAX am Dienstagmittag (finanzen.at) |
Analysen zu EVOTEC SEmehr Analysen
25.11.24 | EVOTEC Sell | Deutsche Bank AG | |
22.11.24 | EVOTEC Outperform | RBC Capital Markets | |
18.11.24 | EVOTEC Sell | Deutsche Bank AG | |
15.11.24 | EVOTEC Buy | Warburg Research | |
15.11.24 | EVOTEC Outperform | RBC Capital Markets |